ArticleBMC surgery2026
Innovative 3D structured light technology for robotic-assisted surgery in selected spontaneous medium-volume basal ganglia hematomas: enhancing precision, surgical nuance, and clinical outcomes.
Article in BMC surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundA structured-light robotic system enables noninvasive surface-based facial registration for patient-to-image alignment; however, it has not been widely adopted for basal ganglia hematoma treatment. This study evaluates its safety, accuracy, and efficiency in patients with basal ganglia hematomas.
methodsRetrospective consecutive patients with spontaneous basal ganglia hematomas (10-30 mL) admitted from January 2022 to January 2024 were grouped as surgical or non-surgical. Outcomes were analyzed, focusing on registration accuracy and surgical efficiency.
resultsBaseline preoperative hematoma volume, GCS, NIHSS, and coagulation disorders were comparable between groups (p > 0.05). Mean registration time was 120 ± 56 s and surgery time 102.22 ± 6.33 min; hematoma clearance was 72% initially and 93% at 7 days. Entry-point discrepancy was 2.2 ± 0.7 mm; catheter tip alignment in the upper/middle/lower hematoma segments was 4%/80%/16%, with a maximum 5.7-mm deviation from the midline axis. The surgery group showed faster recovery with higher 24 h-GCS (p < 0.001) and better NIHSS/ADL/mRS than non-surgery (p < 0.001 at all time points; p = 0.003 and p = 0.026 at 30 and 90 days; p = 0.041). At 90 days, facial palsy, sensory loss, and ulcers were similar (p > 0.05), whereas pneumonia (p = 0.034) and UTIs (p = 0.002) were lower in the surgery group. No mortality, bleeding, or reoperations occurred.
conclusionsSurface registration using the 3D structured light technique is a fast and precise alternative treatment for selected patients with spontaneous medium-volume basal ganglia hematomas, which can improve clinical efficiency while maintaining sufficient accuracy and safety to meet clinical requirements.
trial registrationretrospectively registered with approval by the Ethics Committee of Shanghai Fourth people's hospital, Tongji University School of Medicine (No. 2022327-001).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.